An independent peptide reference — no sellers, every claim sourced

sh-Oligopeptide-1

Also known as Oligopeptide-1, rhEGF, Recombinant human epidermal growth factor, sh-EGF, Human Oligopeptide-1

Recombinant human EGF sold in topical skincare; the evidence and the criticism of it are both substantial.

early-clinical Skin & cosmetic cosmetic ingredient

At a glance

Category
Skin & cosmetic
Status
cosmetic ingredient
Made from
recombinant Expressed in engineered host cells rather than extracted from human tissue. Production hosts vary by manufacturer and include bacteria, yeast and, in at least one commercialised case, barley plants engineered to produce a human-like EGF protein 4.
Route
topical, in a serum, cream or ampoule; also applied after microneedling or laser resurfacing, which is a materially different exposure
Half-life
Not established for topical application. No published pharmacokinetic study measures how long the molecule persists or in what form after being applied to intact skin
Onset
Open-label and controlled studies report changes from about 4 weeks, continuing over 12 weeks 34
Molecular weight
approximately 6.2 kDa for the native 53-residue protein. Reviews describing EGF as too large to penetrate skin often quote figures above 15 kDa, which refer to larger growth factor preparations rather than to the 6 kDa molecule most cosmetic products contain 3
Sequence
A 53-amino-acid polypeptide corresponding to human epidermal growth factor

sh-Oligopeptide-1 is the INCI name under which recombinant human epidermal growth factor is sold as a cosmetic ingredient. The 'sh-' prefix denotes synthetic human, meaning the molecule is produced in engineered cells rather than extracted from human tissue. Its regulatory position is genuinely odd and worth stating precisely: as a cosmetic it is permitted for general use at a range of concentrations, while topical recombinant human EGF is not authorised as a medicine at any concentration outside clinical trials 1. The same molecule is therefore freely available in a serum and unavailable as a drug, and a 2023 critique in Cutaneous and Ocular Toxicology treats that asymmetry as the central problem with the ingredient 1.

Doping status: Not listed by name on the WADA Prohibited List. Growth factors are addressed by class in section S2 of the List, but topical cosmetic use is not a plausible route to a systemic effect and PeptideX will not assert a section number it cannot support for this preparation.

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

The 'human' in 'recombinant human EGF' refers to the sequence, not to the source material — no human donor tissue is involved. That matters to anyone weighing the donor question that attaches to genuinely human-derived products, and it is also the distinction manufacturers rely on when marketing a growth factor as a cosmetic. It does not answer the separate question, addressed below, of whether the molecule in a given product is intact and biologically active.

Mechanism of action

Epidermal growth factor binds the EGF receptor on keratinocytes and fibroblasts and drives proliferation, migration and matrix production. It is a real and well-characterised signalling protein with an established role in wound healing, and there is nothing speculative about what it does when it reaches its receptor. The cosmetic proposition is that the same signalling, applied to photoaged rather than wounded skin, produces the repair response — thicker epidermis, more collagen, improved texture.

Whether a topically applied protein reaches that receptor through intact skin is the question the whole category turns on, and it is not settled. The standard objection is that a protein of this size cannot cross an undamaged stratum corneum in a meaningful quantity. The standard reply is that most commercial products use a roughly 6 kDa rhEGF, which reviews describe as having good potential for topical penetration, with entry additionally possible through hair follicles and sweat glands, and greatly increased by microneedling or laser pretreatment 3. Both positions are argued from plausibility rather than from a measurement of how much intact, active EGF reaches viable epidermis after a cosmetic application, which has not been published.

A 2023 analysis in Cutaneous and Ocular Toxicology goes further than the penetration argument. Reviewing the available literature and approaching the manufacturers directly for data, its author concluded that sh-oligopeptide-1 is not a functional EGF at all — that the preclinical bioactivity of the marketed molecule has not been demonstrated, and that clinical studies using it as though it were equivalent to functional recombinant human EGF therefore lack a scientific basis 1. That is a serious charge from a peer-reviewed source and it is not addressed by the trials that report benefit, because those trials assume the activity rather than verify it. A reader should hold both facts at once: controlled studies report improvement, and a peer-reviewed critique argues the active ingredient may not be active.

What the research shows

Two bodies of work point in opposite directions. A 2021 systematic review of EGF in aesthetics gathered 49 articles covering 821 patients, including 15 randomised controlled trials, and reported improvements in firmness, hydration, periocular wrinkles and pore size 3. A 2023 critique in Cutaneous and Ocular Toxicology argues the cosmetic-grade molecule has never been shown to be biologically active and that the trials are therefore built on an unverified premise 1. Neither position can be dismissed, and the entry does not resolve them.

Research in humans

Randomised and controlled topical studies do report benefit. The 2021 systematic review counted 15 randomised controlled trials among its 49 included articles and found improved firmness, hydration and periocular wrinkles, with reduced rhytids and pore size; it also reported that intradermal injection produced greater and longer-lasting reduction of rhytids than topical application, which is a result that cuts against the topical claim rather than supporting it 3. Individual studies are mostly small and often uncontrolled: Schouest and colleagues (2012) is a three-month open-label single-centre study in 29 women with no control arm, reporting significant improvement in fine lines, texture, pore size and dyschromia 4. A 2026 randomised, double-blinded pilot in 20 women aged 50 to 65 compared a recombinant EGF serum against a human-derived growth factor serum over 12 weeks, favouring the recombinant arm on investigator-rated texture and firmness while global wrinkle severity changed minimally in both 5 — note that this design has no vehicle control, so it compares two actives rather than showing either beats a moisturiser. The critique in Cutaneous and Ocular Toxicology examined 12 selected articles, of which nine were clinical trials treating sh-oligopeptide-1 as equivalent to functional recombinant human EGF, and concluded that these studies do not follow medical standards and that the underlying bioactivity was never established 1.

Animal and lab research

Preclinical EGF research is extensive and concerns wound healing rather than cosmetic use, and it delivers the protein directly to tissue. It establishes what EGF does; it says nothing about what a serum does through intact skin.

Caveats. Beyond the unresolved question of whether the cosmetic molecule is active 1, the practical limitations are severe. Almost every positive study is small, short, industry-connected, or lacks a vehicle-controlled arm — the two most-cited are an uncontrolled open-label series 4 and a 20-subject active-comparator pilot 5. Products differ in molecular form, concentration, host organism and stability, and a protein in an aqueous cosmetic has a stability problem that is rarely documented on the label. There is also a safety question no trial is powered to answer: growth factors drive cell proliferation, most users are applying them to actinically damaged skin, and there is a theoretical concern that they could promote growth of premalignant or malignant cells 6. No evidence of this has been reported, and no study has been designed or run long enough to detect it.

What it is used for

  • Topical anti-ageing serums and creams aimed at fine lines, texture, firmness and pore size 34
  • Post-procedure application after fractional laser resurfacing, microneedling or chemical peel, where the barrier is deliberately disrupted and delivery is genuinely improved — this is the use with the clearest pharmacological logic and, by the same token, the use where the theoretical proliferation concern is most relevant 6
  • Marketed as the active in 'growth factor' skincare, a category positioned as a step beyond peptides
  • Sold as a cosmetic at concentrations for which no long-term risk data exist, while the identical molecule is not authorised as a topical medicine at any concentration 1

Dosing

Dose
Product concentrations are typically expressed in parts per million or as a percentage of a trade solution and vary by an order of magnitude between products; no concentration has been established as effective in a vehicle-controlled trial
Frequency
Once to twice daily in the published studies
Route
topical — this is a cosmetic ingredient, not an injectable
Duration
Published studies ran 12 weeks. Any effect stops when use stops
  • No dose-response study for topical rhEGF as a cosmetic has been published. Concentration figures on packaging come from formulators, not from clinical dose-finding.
  • The 2021 systematic review reported that intradermal injection outperformed topical application 3. That is a finding about delivery, and it undercuts rather than supports the topical product — it is not a reason to inject a cosmetic serum, which is not sterile, not pyrogen-free and has never been studied by that route.
  • Applying this after microneedling or laser is applying it to skin whose barrier has been removed. Exposure is much higher than the topical studies represent, and neither the efficacy data nor the safety data were generated under those conditions.
  • Anyone with a personal history of skin cancer, or with actinic keratoses, may reasonably decide the theoretical proliferation concern 6 is not worth accepting for a cosmetic benefit of contested size.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Reconstitution

Vial sizes
Supplied to formulators as a solution or lyophilised powder; to consumers as a finished serum, cream or ampoule
Solvent
the aqueous phase of a formulation; not bacteriostatic water for injection — this ingredient is not reconstituted for injection
Storage
Many products specify refrigeration. A recombinant protein in an aqueous cosmetic is subject to denaturation and proteolysis, and few products publish stability data supporting their shelf life.

Added cold, late in manufacture. Heat, extreme pH and long ambient storage are all plausible routes to an inactive product, which is one reason the question of whether the marketed molecule is functional cannot be answered from the label.

Safety

Side effects

  • Reported adverse effects in the aesthetic literature are minimal and transient: pruritus, mild inflammation, burning and erythema, the last mostly associated with microneedling rather than the ingredient 3
  • Most studies reported no adverse events at all 3 — in short studies, in small numbers, over 12 weeks
  • Irritation or stinging on freshly resurfaced or abraded skin
  • Theoretical concern that growth factors could promote proliferation of premalignant or malignant cells, which is relevant because the typical user is applying them to sun-damaged skin; no such event has been reported, and no study has been designed to detect one 6
  • The absence of long-term safety data for an ingredient sold for general cosmetic use is itself a finding 1

Do not use if

  • Known or suspected skin malignancy, actinic keratosis or a personal history of skin cancer in the treatment area — the theoretical proliferation concern applies most directly here and there is no data to reassure against it 6
  • Known hypersensitivity to the ingredient or the formulation
  • Active infection or inflammation at the application site
  • Pregnancy and breastfeeding: no specific research on this ingredient
  • Do not apply to mucous membranes or in the eyes
  • Injecting a cosmetic serum containing this ingredient has never been studied in humans, and cosmetic preparations are not sterile or pyrogen-free

Interactions

Not systematically studied. No systemic drug interaction is expected from topical use, though systemic exposure has not been measured for this molecule. Within a formulation the protein is sensitive to pH, heat and preservative systems. Concurrent use with retinoids or exfoliating acids raises irritation and, by disrupting the barrier, increases delivery of an ingredient whose optimal exposure is unknown. Use immediately after microneedling or ablative laser is common practice and changes exposure substantially; it has not been characterised in a published pharmacokinetic study.

Sources